Vericel Corp (VCEL)
Vericel Corp (VCEL) from its SEC filings: 2025 revenue $276.3 million (+16% vs the year before), net margin 6%, free cash flow $24.7 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $276.3 million |
| Revenue growth | +16% |
| Net income | $16.5 million |
| Net margin | 6.0% |
| Free cash flow | $24.7 million |
| Diluted EPS | $0.32 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +22% |
| Cash | $125.4 million |
| Long-term debt | $13.2 million |
| Share count, 1 year | +2% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.